Sfoglia per AUTORE
ANTONUZZO L
Collezione AOU San Luigi di Orbassano

  

Items : 14

A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2024 Sep;208:114129. doi: 10.1016/j.ejca.2024.114129. Epub 2024 May 25.
2024
AOU San Luigi di Orbassano

Bongiovanni A; Liverani C; Foca F; Bergamo F; Leo S; Pusceddu S; Gelsomino F; Brizzi MP; Di Meglio G; Spada F; Tamberi S; Lolli I; Cives M; Marconcini R; Pucci F; Berardi R; Antonuzzo L; Badalamenti G; Santini D; Recine F; Vanni S; Tebaldi M; Severi S; Rudnas B; Nanni O; Ranallo N; Crudi L; Calabrò L; Ibrahim T; et alii...

Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial. in International journal of cancer / Int J Cancer. 2022 Nov 15;151(10):1760-1769. doi: 10.1002/ijc.34156. Epub 2022 Jun 23.
2022
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Morano F; Pietrantonio F; Di Maio M; Di Bartolomeo M; Rossi A; Giordano M; Antonuzzo L; Petrelli F; Ratti M; Berenato R; Clavarezza M; Zaniboni A; Murialdo R; Tampellini M; Fanchini L; Antoniotti C; Bozzarelli S; Sartore-Bianchi A; Lonardi S; Pagani F; Randon G; Prisciandaro M; Raimondi A;

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. in Journal of hematology & oncology / J Hematol Oncol. 2022 Jan 21;15(1):9. doi: 10.1186/s13045-022-01226-2.
2022
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Russo A; Porzio G; Tiseo M; Russano M; Ficorella C; Addeo A; Banna GL; Friedlaender A; Spinelli GP; Metro G; Migliorino MR; Passiglia F; Ricciardi S; Zoratto F; Pecci F; Di Marino P; Mansueto G; De Tursi M; Tuzi A; Gori S; Della Gravara L; Macerelli M; Rastelli F; Chiari R; Gelibter A; Marchetti P; Antonuzzo L; Mazzoni F; et alii...

Post-progression outcomes of NSCLC patients with PD-L1 expression ? 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 May;148:24-35. doi: 10.1016/j.ejca.2021.02.005. Epub 2021 Mar 12.
2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Ficorella C; Addeo A; Friedlaender A; Banna GL; Di Maio M; Spinelli GP; Russo A; Adamo V; De Filippis M; Metro G; Simona C; Natalizio S; Migliorino MR; Landi L; Ricciardi S; Buti S; Minuti G; Nigro O; Cantini L; Bracarda S; Citarella F; Russano M; Filetti M; Zoratto F; Gori S; De Tursi M; Mansueto G; Rocco D; et alii...

Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. in Thoracic cancer / Thorac Cancer. 2021 Mar;12(6):880-889. doi: 10.1111/1759-7714.13852. Epub 2021 Feb 1.
2021
AOU San Luigi di Orbassano

Cortellini A; De Giglio A; Cannita K; Cortinovis DL; Cornelissen R; Baldessari C; Giusti R; D'Argento E; Grossi F; Santoni M; Catino A; Berardi R; Sforza V; Rossi G; Antonuzzo L; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Follador A; Rastelli F; Chiari R; Gravara LD; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; et alii...

Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer / Support Care Cancer. 2021 Jul;29(7):3971-3980. doi: 10.1007/s00520-020-05972-2. Epub 2021 Jan 3.
2021
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

de Braud F; Di Bartolomeo M; Pietrantonio F; Randon G; Prisciandaro M; Ambrosini M; Pagani F; Niger M; Antista M; Longarini R; Cinieri S; Giordano M; Antonuzzo L; Petrelli F; Toscano G; Tomasello G; Zaniboni A; Clavarezza M; Murialdo R; Tampellini M; Racca P; Amatu A; Rimassa L; Antoniotti C; Morano F; Lonardi S; Corallo S; Raimondi A;

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ? 50% and Their Relationship With Clinical Outcomes. in Clinical lung cancer / Clin Lung Cancer. 2020 Nov;21(6):498-508.e2. doi: 10.1016/j.cllc.2020.06.010. Epub 2020 Jun 21.
2020
AOU San Luigi di Orbassano

Cortellini A; Friedlaender A; Banna GL; Porzio G; Bersanelli M; Cappuzzo F; Aerts JGJV; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Berardi R; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Inno A; Di Marino P; Mansueto G; Zoratto F; et alii...

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ??50. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2020 Nov;69(11):2209-2221. doi: 10.1007/s00262-020-02613-9. Epub 2020 May
2020
AOU San Luigi di Orbassano

Cortellini A; Tiseo M; Banna GL; Cappuzzo F; Aerts JGJV; Barbieri F; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Santini D; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; et alii...

Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2020 Aug;135:230-239. doi: 10.1016/j.ejca.2020.04.048. Epub 2020 Jul 2.
2020
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Pietrantonio F; Di Bartolomeo M; Peverelli G; de Braud F; Antista M; Niger M; Bergamo F; Cinieri S; Longarini R; Giordano M; Antonuzzo L; Petrelli F; Adamo V; Tomasello G; Zaniboni A; Clavarezza M; Murialdo R; Tampellini M; Ritorto G; Sartore-Bianchi A; Rimassa L; Antoniotti C; Corallo S; Lonardi S; Morano F; Raimondi A; Di Maio M; Raimondi A; Di Maio M; et alii...

Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. in Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] / Pancreatology. 2018 Mar;18(2):198-203. doi: 10.1016/j.pan.2018.01.005. Epub 2018 Jan 12.
2018
AOU San Luigi di Orbassano

Rinzivillo M; Fazio N; Pusceddu S; Spallanzani A; Ibrahim T; Campana D; Marconcini R; Partelli S; Badalamenti G; Brizzi MP; Catena L; Schinzari G; Carnaghi C; Berardi R; Faggiano A; Antonuzzo L; Spada F; Gritti S; Femia D; Gelsomino F; Bongiovanni A; Ricci S; Brighi N; Falconi M; Delle Fave G; Panzuto F;

A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. in Endocrine-related cancer / Endocr Relat Cancer. 2018 Jun;25(6):607-618. doi: 10.1530/ERC-17-0489. Epub 2018 Mar 20.
2018
AOU San Luigi di Orbassano

Pusceddu S; Barretta F; Trama A; Botta L; Milione M; Buzzoni R; De Braud F; Mazzaferro V; Pastorino U; Seregni E; Mariani L; Gatta G; Di Bartolomeo M; Femia D; Prinzi N; Coppa J; Panzuto F; Antonuzzo L; Bajetta E; Brizzi MP; Campana D; Catena L; Comber H; Dwane F; Fazio N; Faggiano A; Giuffrida D; Henau K; Ibrahim T; et alii...

Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. in Gastroenterology / Gastroenterology. 2018 Aug;155(2):479-489.e7. doi: 10.1053/j.gastro.2018.04.010. Epub 2018 Apr 13.
2018
AO Cuneo
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Mazzaferro V; Buzzoni R; Delle Fave G; Giacomelli L; Milione M; Lo Russo G; Concas L; Femia D; Prinzi N; Garattini SK; Bajetta E; Tafuto S; Di Costanzo F; Torniai M; Zaniboni A; Ortolani S; Puliafito I; Panzuto F; Colao A; Brighi N; La Salvia A; Cavalcoli F; Bongiovanni A; Fazio N; Ricci S; Duro M; Davì MV; Cauchi C; Carnaghi C; et alii...

Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. in Cancer medicine / Cancer Med. 2017 Jul;6(7):1493-1499. doi: 10.1002/cam4.1028. Epub 2017 May 25.
2017
AOU San Luigi di Orbassano

Berardi R; Torniai M; Pusceddu S; Spada F; Ibrahim T; Brizzi MP; Antonuzzo L; Ferolla P; Panzuto F; Silvestris N; Partelli S; Ferretti B; Freddari F; Gucciardino C; Testa E; Concas L; Murgioni S; Bongiovanni A; Zichi C; Riva N; Rinzivillo M; Brunetti O; Giustini L; Di Costanzo F; Delle Fave G; Fazio N; De Braud F; Falconi M; Cascinu S; et alii...

Real-world study of everolimus in advanced progressive neuroendocrine tumors. in The oncologist / Oncologist. 2014 Sep;19(9):966-74. doi: 10.1634/theoncologist.2014-0037. Epub 2014 Aug 12.
2014
AOU San Luigi di Orbassano

Panzuto F; Rinzivillo M; Fazio N; de Braud F; Luppi G; Zatelli MC; Lugli F; Tomassetti P; Riccardi F; Nuzzo C; Brizzi MP; Faggiano A; Zaniboni A; Nobili E; Pastorelli D; Cascinu S; Merlano M; Chiara S; Antonuzzo L; Funaioli C; Spada F; Pusceddu S; Fontana A; Ambrosio MR; Cassano A; Campana D; Cartenì G; Appetecchia M; Berruti A; et alii...